Farxiga Tablet, Film Coated
Product Images NDC 50090-3482

18 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Farxiga (NDC 50090-3482). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Dapagliflozin Chemical Structure (Dapagliflozin Struct)

Dapagliflozin Chemical Structure (Dapagliflozin Struct)
Chemical structure of the active ingredient dapagliflozin, showing its molecular components including a glucose moiety, chlorine-substituted aromatic rings, an ethoxy group, and associated hydration with water molecules.*
FDA Label Image

Figure 1 (Farxiga Fig1)

Figure 1 (Farxiga Fig1)
A scatter plot comparing dapagliflozin dose (mg) on the x-axis with change from baseline in 24-hour urinary glucose (g) on the y-axis. The chart shows observed values for healthy subjects and subjects with type 2 diabetes mellitus (T2DM), with distinct fitted lines for each group illustrating the dose-response relationship.*
FDA Label Image

Figure-2 (Firgure 2)

Figure-2 (Firgure 2)
A line graph depicting the adjusted mean change from baseline in HbA1c (%) over 24 weeks of study comparing FARXIGA 10 mg alone, FARXIGA 10 mg with Metformin, and Metformin alone. The x-axis shows study weeks, and the y-axis shows percentage change in HbA1c. The graph includes mean values with confidence intervals at week 24 using last observation carried forward (LOCF).*
FDA Label Image

Figure-3 (Firgure 3)

Figure-3 (Firgure 3)
A line graph depicting the adjusted mean change from baseline in HbA1c (%) over 24 study weeks comparing FARXIGA 10 mg plus Metformin to Placebo plus Metformin. The graph shows a greater decrease in HbA1c for FARXIGA 10 mg plus Metformin. Error bars at week 24 present confidence intervals for both groups.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A line graph comparing the percentage of patients with an event over 60 months from randomization between FARXIGA and placebo. The y-axis represents patients with event (%) and the x-axis shows months from randomization. FARXIGA has a consistently lower percentage of patients with events compared to placebo. Patient counts at risk are listed below the graph for both FARXIGA and placebo at multiple time points.*
FDA Label Image

Figure 5 (Firgure 5)

Figure 5 (Firgure 5)
A line graph depicting the percentage of patients with an event over time in months from randomization, comparing FARXIGA and placebo groups. The y-axis shows patients with events (%) from 0 to 4.5, and the x-axis covers 0 to 60 months. FARXIGA shows a lower event percentage than placebo throughout the period. A table below lists the number of patients at risk at several time points for both groups.*
FDA Label Image

Figure_6 (Figure 6)

Figure_6 (Figure 6)
A Kaplan-Meier curve comparing the percentage of patients with events over months from randomization for FARXIGA (dapagliflozin) versus placebo. The graph shows two lines: a solid line for FARXIGA and a dashed line for placebo, with a lower event rate in the FARXIGA group. Below the graph, the number of patients at risk at specific time points is listed for both groups.*
FDA Label Image

Figure-7a (Figure 7a)

Figure-7a (Figure 7a)
A Kaplan-Meier curve showing the percentage of patients with events over time, comparing FARXIGA and placebo groups. The x-axis represents months from randomization up to 36 months, and the y-axis shows the percentage of patients with events. FARXIGA has a lower event rate than placebo during the study period. A hazard ratio (HR) with confidence interval (CI) and p-value comparing FARXIGA versus placebo are also presented below the graph.*
FDA Label Image

Figure_7b (Figure 7b)

Figure_7b (Figure 7b)
This line graph compares the percentage of patients with events over 36 months from randomization between FARXIGA (dapagliflozin) and placebo. The graph shows two curves, with FARXIGA having a consistently lower percentage of events than placebo. Below the x-axis are patient risk numbers for each group over time. A hazard ratio (HR) of 0.82 with a 95% confidence interval and a p-value of 0.0008 are noted, indicating statistical data for the comparison.*
FDA Label Image

Figure-8a (Figure 8a)

Figure-8a (Figure 8a)
A Kaplan-Meier curve comparing the percentage of patients with events over months from randomization between FARXIGA and Placebo groups. The graph shows patients at risk over time for each group, with FARXIGA consistently showing a lower cumulative event rate compared to Placebo across approximately 30 months.*
FDA Label Image

Figure-8b (Figure 8b)

Figure-8b (Figure 8b)
A Kaplan-Meier curve comparing the percentage of patients with an event over 36 months from randomization for FARXIGA (dapagliflozin) versus placebo. The graph shows two lines, with FARXIGA consistently below placebo, indicating fewer patients with events. The hazard ratio (HR) with 95% confidence interval is provided as 0.88 (0.74, 1.05). Patient risk counts at various time points are displayed below the x-axis.*
FDA Label Image

Figure-9a (Figure 9a)

Figure-9a (Figure 9a)
A line chart comparing the percentage of patients experiencing an event over 24 months between FARXIGA and placebo groups. The x-axis represents months from randomization, while the y-axis shows the percentage of patients with the event. FARXIGA shows a lower event rate than placebo. Patient numbers at risk for each group are listed below the graph.*
FDA Label Image

Figure-9b (Figure 9b)

Figure-9b (Figure 9b)
A line graph comparing the percentage of patients with events over 36 months between FARXIGA and placebo groups. The x-axis represents months from randomization, and the y-axis shows the percentage of patients with events. FARXIGA shows a consistently lower event rate than placebo. Patient numbers at risk over time are listed below the graph.*
FDA Label Image

Figure 10a (Figure 10a)

Figure 10a (Figure 10a)
A forest plot chart showing hazard ratios (HR) with 95% confidence intervals (CI) comparing FARXIGA (dapagliflozin) versus placebo across various patient characteristics for a primary composite endpoint. The chart includes groups by age, sex, race, geographic region, NYHA class, NT-proBNP level, prior hospitalization for heart failure, MRA use at baseline, type 2 diabetes status, atrial fibrillation/flutter presence, heart failure etiology, BMI, and baseline eGFR. HR values favor FARXIGA when left of center, indicating better outcomes compared to placebo.*
FDA Label Image

Figure-10b (Figure 10b)

Figure-10b (Figure 10b)
This forest plot chart compares hazard ratios (HR) with 95% confidence intervals for various patient characteristics between FARXIGA (dapagliflozin) and placebo groups in a clinical study. It presents data subgroups by age, sex, race, geographic region, NYHA class, NT-proBNP levels, diabetes status at enrollment, atrial fibrillation, BMI, baseline eGFR, and systolic blood pressure, illustrating relative treatment effects.*
FDA Label Image

Figure_11 (Figure 11)

Figure_11 (Figure 11)
A forest plot chart comparing the hazard ratios (HR) with 95% confidence intervals for FARXIGA versus placebo across different left ventricular ejection fraction (LVEF) percentage categories in two clinical study groups, DAPA-HF and DELIVER. The chart visually represents relative outcomes with numeric data detailing participant counts and HR values for each LVEF category.*
FDA Label Image

Label Image (Lbl500903481)

Label Image (Lbl500903481)
FARXIGA 10 mg film-coated tablets label from A-S Medication Solutions. The label specifies that each tablet contains the equivalent of 10 mg dapagliflozin as dapagliflozin propanediol. Storage instructions indicate to keep the product at 68 to 77 degrees Fahrenheit. The package contains 30 tablets. Additional information includes lot number, product number, barcodes, and distributor details.*
FDA Label Image

Label Image (Lbl500903482)

Label Image (Lbl500903482)
FARXIGA 5 mg film-coated tablets label from A-S Medication Solutions. The label includes the active ingredient dapagliflozin and instructs storage at 68 to 77 degrees Fahrenheit. It specifies a package containing 30 tablets and includes the National Drug Code (NDC) 50090-3482-0 along with the product number, lot, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.